Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. [electronic resource]
Producer: 20180221Description: 635-647 p. digitalISSN:- 1179-1926
- Antigens, CD20 -- metabolism
- Antineoplastic Agents -- blood
- B-Lymphocytes -- metabolism
- Body Surface Area
- Female
- Genotype
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Lymphocyte Count
- Male
- Middle Aged
- Models, Biological
- Polymorphism, Genetic
- Receptors, IgG -- genetics
- Rituximab -- blood
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.